News und Analysen
Illumina Welcomes Kathryne Reeves as Chief Marketing Officer
Illumina (NASDAQ: ILMN) announced today that Kathryne Reeves will join the company as Chief Marketing Officer on September 28, 2020. Reeves brings more than 25 years of marketing and general
Illumina Welcomes Kathryne Reeves as Chief Marketing Officer
Illumina (NASDAQ: ILMN) announced today that Kathryne Reeves will join the company as Chief Marketing Officer on September 28, 2020. Reeves brings more than 25 years of marketing and general
Illumina Welcomes Kathryne Reeves as Chief Marketing Officer
Illumina (NASDAQ: ILMN) announced today that Kathryne Reeves will join the company as Chief Marketing Officer on September 28, 2020. Reeves brings more than 25 years of marketing and general
Premier, Inc. Reports Fiscal 2020 Fourth-Quarter and Full-Year Results
Premier, Inc. (NASDAQ: PINC) today reported financial results for the fiscal year (FY) 2020 fourth quarter and full year ended June 30, 2020.
All results presented in this press release reflect
Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting
Ipsen (Euronext: IPN; ADR: IPSEY) today announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP), to be presented during
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against
Quidel Concludes Sofia® SARS Antigen Investigation From Vermont
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that labeling for
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of interim results from its Phase II CONTROL trial of neratinib in the September 2020 Issue (Volume
Momenta Pharmaceuticals: Nächste Mega-Übernahme im US-Biotechsektor!
Zuletzt verging kaum ein Tag, an dem nicht irgendeine Mega-Übernahme im US-Biotechsektor vermeldet wurde. So auch heute. Denn heute verkündete Johnson & Johnson die Übernahme von Momenta
Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.26 billion for the third quarter ended July 31, 2020, a decline of 1% compared to the third quarter of 2019 and down 3.1% on a core(
Premier Inc. Working with AstraZeneca to Reduce Hospitalizations of Patients with Hyperkalemia
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today it has reached a significant milestone in its partnership with AstraZeneca, a global, science-led
Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics
Agilent Technologies Inc. (NYSE: A) today announced it will expand its state-of-the-art production facility in Frederick, Colorado, that develops and manufactures “oligos,” which are short DNA and
Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company’s switch-control tyrosine
Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that data from the Phase 2 TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Novocure Announces Expansion of Its Executive Leadership Team
Novocure (NASDAQ:NVCR) today announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020, intended to further solidify executive leadership in preparation for an anticipated
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020
LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the
Dexcom Appoints Karen Dahut to Board of Directors
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately.
Ms
Dexcom Appoints Karen Dahut to Board of Directors
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately.
Ms
Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture